Business

Mass. Movers

Analysts raise price target on Insulet

A diabetic tests his blood-sugar level.

Associated Press/File 2009

A diabetic tests his blood-sugar level.

Advertisement

Canaccord Genuity analysts set a $37 price target on Insulet Corp. stock, dailypolitical.com reported. The firm currently rates the stock a “buy.” “Management has positively commented . . . that new patient growth remains robust,” analysts wrote. In the most recent quarter, revenue rose 20 percent, compared to the same quarter last year. Bedford-based Insulet makes the OmniPod Insulin Management System for people with insulin-dependent diabetes.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com